PPCBHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 22 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Propanc Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (97): Smaller than most of the companies we track.
Value (18): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PPCB, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PPCB appears in the Radar on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 75% of US stocks
Cheaper than 89% of US stocks
Cheaper than 63% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 9% of US stocks
Higher than 5% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Propanc Biopharma, Inc. has a market value of $3.1M and an enterprise value of $1.7M.
Revenue in the twelve months to 31 Mar 2026: $0.0.
Net income over the same four quarters: −$18.4M.
Free cash flow in the twelve months to 31 Mar 2026: −$4.1M.
Trailing P/E: 0.0×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Propanc Biopharma, Inc. employs 2 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Propanc Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Propanc Biopharma announced that it is implementing a reverse stock split, as indicated by the headline. The supplied excerpt contains no additional details.
Why it matters — PPCB watchers may note the reverse stock split in the context of the company’s stated aim to support continued Nasdaq listing and growth plans.
Propanc Biopharma said its board approved a 1-for-10 reverse split of the company’s issued and outstanding common shares. The split is anticipated to take effect at market open on October 26, 2026.
Why it matters — PPCB watchers may note the announced share restructuring, which the headline says is intended to support continued Nasdaq listing and the company’s growth plans.
Propanc Biopharma announced preclinical research from an academic–industry collaboration led by Dr. Maria Belén Toledo that identified its pancreatic proenzyme formulation, PRP, as a potential approach to chemotherapy resistance in pancreatic cancer. The announcement describes how resistant tumor cells can adopt adaptive states that support survival and aggressive characteristics.
Why it matters — The research concerns PPCB’s lead asset and its potential relevance to chemotherapy-resistant pancreatic cancer, but the excerpt provides no further study results.
Propanc Biopharma announced publication of a peer-reviewed pilot study in Scientific Reports evaluating its PRP formulation, a fixed-ratio combination of Trypsinogen and Chymotrypsinogen A, in pancreatic and ovarian cancer.
Why it matters — The publication provides PPCB watchers with an update on research evaluating the company’s proprietary PRP formulation.
Propanc Biopharma reported preclinical data showing 90% tumor growth inhibition with PRP in pancreatic cancer models and compared PRP’s profile with daraxonrasib, which was approved for certain adults with metastatic pancreatic adenocarcinoma.
Why it matters — The report highlights PPCB’s preclinical PRP findings alongside an approved treatment used as a clinical benchmark in pancreatic cancer.
As at 22 Oct 2026, Propanc Biopharma, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (97 of 100).
No analyst covering Propanc Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PPCB are extrapolating price history, which says nothing about the business.
Propanc Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments for patients with pancreatic, ovarian, and colorectal cancers.
The most recent item we track (GlobeNewsWire, 22 Oct 2026): "CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans". Propanc Biopharma announced that it is implementing a reverse stock split, as indicated by the headline. The supplied excerpt contains no additional details.
Propanc Biopharma, Inc. is a clinical-stage biopharmaceutical company focused on developing cancer treatments for patients with pancreatic, ovarian, and colorectal cancers. The company’s current work centers on proenzyme-based therapies designed to address recurring and metastatic disease, with an emphasis on helping control tumor spread and reduce recurrence. Its product pipeline includes lead candidates such as PRP and POP1, which are being developed as long-term therapeutic options for solid tumors. Propanc Biopharma operates in the oncology-focused biotechnology segment of the life sciences market, where it contributes to the development of novel approaches for chronic and advanced cancer care. Headquartered in Camberwell, Australia, the company is positioned as a specialized developer of experimental cancer therapies for use in clinical and preclinical settings.
CEO Mr. James Nathanielsz · 2 employees · Australia · https://www.propanc.com